Clinical Trials
10 trialsNCT03223610 2026-05-22
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT07600151 2026-05-20
CONQUISTADOR
Universitätsklinikum Hamburg-Eppendorf
Phase 1/2 Not yet recruiting
NCT04661007 2026-05-18
J-MIND
Incyte Corporation
Phase 1/2 Active not recruiting
NCT05683171 2026-05-15
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04126200 2026-05-06
DREAMM 5
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT04542824 2026-05-05
EPCORE™ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT04623541 2026-05-05
EPCORE™ CLL-1
Genmab
Phase 1/2 Active not recruiting
NCT04663347 2026-05-05
EPCORE™ NHL-2
Genmab
Phase 1/2 Active not recruiting
NCT02343042 2026-05-04
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Active not recruiting
NCT05583617 2026-05-04
PLYCOM
Hoffmann-La Roche
Phase 1/2 Recruiting